James Richard Baker

James Richard Baker

Auto-generated profile, based on publicly available information

James Richard Baker

Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2010 in Journal of the American Chemical Society
Verified
Journal Article
Open access
MSMark E. B. Smith
Mark E. B. Smith
FSFelix F. Schumacher
Felix F. Schumacher
CRChris P. Ryan
Chris P. Ryan
LTLauren M. Tedaldi
Lauren M. Tedaldi
DPDanai Papaioannou
Danai Papaioannou
JBJames R. Baker
James R. Baker
The maleimide motif is widely used for the selective chemical modification of cysteine residues in proteins. Despite widespread utilization, there are some potential limitations, including the irreversible nature of the reaction and, hence, the modification and the number of attachment positions. We conceived of a new class of maleimide which would address some of these limitations and provide new opportunities for protein modification. We report herein the use of mono- and dibromomaleimides for reversible cysteine modification and illustrate this on the SH2 domain of the Grb2 adaptor protein (L111C). After initial modification of a protein with a bromo- or dibromomaleimide, it is possible to add an equivalent of a second thiol to give further bioconjugation, demonstrating that bromomaleimides offer opportunities for up to three points of attachment. The resultant protein−maleimide products can be cleaved to regenerate the unmodified protein by addition of a phosphine or a large excess of a thiol. Furthermore, dibromomaleimide can insert into a disulfide bond, forming a maleimide bridge, and this is illustrated on the peptide hormone somatostatin. Fluorescein-labeled dibromomaleimide is synthesized and inserted into the disulfide to construct a fluorescent somatostatin analogue. These results highlight the significant potential for this new class of reagents in protein modification.

27 April 2020 in ACS Chemical Biology
Verified
Journal Article
Open access
MMMarı́a Maneiro
Marı́a Maneiro
NFNafsika Forte
Nafsika Forte
MSMaria M. Shchepinova
Maria M. Shchepinova
CKCyrille S. Kounde
Cyrille S. Kounde
VCVijay Chudasama
Vijay Chudasama
ETEdward W. Tate
Edward W. Tate
Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery. Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity, and do not discriminate between cells of different types. Here we describe a strategy for selec-tive protein degradation in a specific cell type. We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internal-ization, releasing the active PROTAC and inducing catalytic protein degradation. We show that 3 selectively targets bromodomain-containing protein 4 (BRD4) for degradation only in HER2 positive breast cancer cell lines, whilst sparing HER2 negative cells. Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 positive cells, leading to release of active PROTAC in quantities sufficient to induce potent BRD4 degradation. These studies demonstrate proof-of-concept for tissue-specific BRD4 degradation, overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.

7 August 2014 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
FSFelix F. Schumacher
Felix F. Schumacher
JNJoão P. M. Nunes
João P. M. Nunes
AMAntoine Maruani
Antoine Maruani
VCVijay Chudasama
Vijay Chudasama
MSMark E. B. Smith
Mark E. B. Smith
SCStephen Caddick
Stephen Caddick
Highly homogeneous ADCs are generated by the efficient bridging of interchain disulfide bonds in trastuzumab, using next generation maleimides.

13 January 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MJMathew W. Jones
Mathew W. Jones
RSRachel A. Strickland
Rachel A. Strickland
FSFelix F. Schumacher
Felix F. Schumacher
SCStephen Caddick
Stephen Caddick
JBJames. R. Baker
James. R. Baker
DHDavid M. Haddleton
David M. Haddleton

27 September 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MHMuhammed Haque
Muhammed Haque
NFNafsika Forte
Nafsika Forte
JBJames R. Baker
James R. Baker
In this feature article we discuss developments in site-selective lysine modification methodologies and their application towards the synthesis of antibody–drug conjugates; including our recent work on a cysteine-to-lysine transfer (CLT) protocol.

27 January 2011 in Bioconjugate Chemistry
Verified
Journal Article
Open access
FSFelix F. Schumacher
Felix F. Schumacher
MNMuriel Nobles
Muriel Nobles
CRChris P. Ryan
Chris P. Ryan
MSMark E. B. Smith
Mark E. B. Smith
ATAndrew Tinker
Andrew Tinker
JBJames R. Baker
James R. Baker
The introduction of non-natural entities into proteins by chemical modification has numerous applications in fundamental biological science and for the development and manipulation of peptide and protein therapeutics. The reduction of native disulfide bonds provides a convenient method to access two nucleophilic cysteine residues that can serve as ideal attachment points for such chemical modification. The optimum bioconjugation strategy utilizing these cysteine residues should include the reconstruction of a bridge to mimic the role of the disulfide bond, maintaining structure and stability of the protein. Furthermore, the bridging chemical modification should be as rapid as possible to prevent problems associated with protein unfolding, aggregation, or disulfide scrambling. This study reports on an in situ disulfide reduction-bridging strategy that ensures rapid sequestration of the free cysteine residues in a bridge, using dithiomaleimides. This approach is then used to PEGylate the peptide hormone somatostatin and retention of biological activity is demonstrated.